Latest Haemophilia Stories
DUBLIN, January 27, 2015 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/pfd99m/recombinant) has announced the addition of the "Recombinant
WHIPPANY, N.J., Dec. 17, 2014 /PRNewswire/ -- Bayer HealthCare has submitted a Biologics License Application (BLA) to the U.S.
CSL Behring Continues Improving Patient Well-Being; Key Milestone Achieved in PROLONG-9FP, Company's Recombinant Factor IX Fusion Protein Development Program KING OF PRUSSIA,
Leading gene therapy Company will partner with established market leader to develop a potential new treatment paradigm for hemophilia B PHILADELPHIA, Dec.
SAN FRANCISCO, December 7, 2014 /PRNewswire/ -- Today, Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia A who had the highest
Twice-Weekly Prophylactic Regimen Resulted in 95% Reduction in Median Annualized Bleed Rate Compared to On-Demand Treatment SAN FRANCISCO, Dec.
PLAINSBORO, N.J., Dec.
DIEPENBEEK, Belgium, November 25, 2014 /PRNewswire/ -- Treatment for haemophilia A patients developing Factor VIII inhibitors Apitope, the drug discovery
Just Released Results from Innovaacom Program Show 94% of Physicians More Confident Treating and Communicating Best Practices for Hemophilia Atlanta, Georgia
Gene therapy pioneered by St.
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.